A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

NCT02845219 · Completed

Last updated 2026-05-28

This trial tests how a diabetes medication called oral semaglutide affects the levels of hormones in birth control pills in healthy postmenopausal women.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 25 people

Who can join Ages 45+ · female only Healthy volunteers accepted.

Timeline Started 2016-07 · est. completion 2016-12

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02845219 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to investigate the influence of oral semaglutide on pharmacokinetics (the exposure of the trial drug in the body) of ethinylestradiol and levonorgestrel in an oral contraceptive combination drug in healthy postmenopausal females.

Treatments tested

semaglutide Drug

Oral administration once daily alone or together with oral contraceptive.
SNAC Drug

Oral administration once daily together with oral contraceptive.
Microgynon® Drug

Oral administration once daily alone or together with oral semaglutide or SNAC.

Main thing measured	Area under the ethinylestradiol plasma concentration-time curve during a dosing interval (0-24 hours) at steady state
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02845219 ↗